U.S. markets closed

Silverback Therapeutics, Inc. (SBTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.28-0.01 (-0.19%)
At close: 04:00PM EDT
5.28 0.00 (0.00%)
After hours: 04:49PM EDT

Silverback Therapeutics, Inc.

500 Fairview Avenue North
Suite 600
Seattle, WA 98109
United States
206 456 2900

Full Time Employees90

Key Executives

NameTitlePayExercisedYear Born
Dr. Laura K. Shawver Ph.D.CEO & Director821.5kN/A1958
Dr. Peter A. Thompson FACP, M.D.Co-Founder & Chairman of DirectorsN/AN/A1960
Mr. Russ HawkinsonSr. VP of Fin., Interim CFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1959
Mr. Miguel Arcinas M.B.A.VP of Corp. Devel. & Investor RelationsN/AN/AN/A
Mr. Jeffrey C. Pepe J.D., Ph.D.Gen. Counsel & Corp. Sec.N/AN/AN/A
Jen MoreDirector of HRN/AN/AN/A
Ms. Sue HamkeSr. VP of Clinical OperationsN/AN/AN/A
Mr. Dario Gobunquin CPASr. Director of Accounting & ControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Corporate Governance

Silverback Therapeutics, Inc.’s ISS Governance QualityScore as of September 28, 2022 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.